← Eichor
Condition: Advanced Or Metastatic Colorectal Cancer Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Advanced Or Metastatic Colorectal Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
Phase 1 · 8 location(s) · Orano Med Theranostics, SAS · NCT05283330First-in-human Phase I Study to Evaluate Safety, Tolerability and Antineoplastic Activity of OATD-02 in Patients with Se
Phase 1 · 3 location(s) · Molecure S.A. · NCT05759923A Study of YL202 in Patients With Advanced Solid Tumors
Phase 2 · 1 location(s) · MediLink Therapeutics (Suzhou) Co., Ltd. · NCT07202364Study of Intratumoral IVX037 in Patients With Advanced or Metastatic Solid Tumours
Phase 1 · 3 location(s) · ImmVirx Pty Ltd · NCT05427487The Phase 1b/IIa, Open-label, Dose Escalation and Dose Expansion to Evaluate Safety, Tolerability, and Preliminary Effic
Phase 1/Phase 2 · 1 location(s) · Chang Gung Memorial Hospital · NCT07204574A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Parti
Phase 2 · 54 location(s) · Bayer · NCT06760819Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
Phase 1/Phase 2 · 6 location(s) · Revolution Medicines, Inc. · NCT07397338First-in-human Trial of STC-1010, an Immunotherapy, in Patients With Unresectable Locally Advanced or Metastatic Colorec
Phase 1/Phase 2 · 9 location(s) · Brenus Pharma · NCT06934538GSL Synthetase Inhibitor Plus Immune Checkpoint Inhibitor and/or Regorafenib in Previously Treated pMMR/MSS CRC.
Phase 2 · 1 location(s) · Chinese PLA General Hospital · NCT06558773A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRC
Phase 1/Phase 2 · 15 location(s) · Anbogen Therapeutics, Inc. · NCT07244705Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
Phase 1 · 122 location(s) · Exelixis · NCT05176483Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pa
Phase 2 · 26 location(s) · Endevica Bio · NCT06937177A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants Wi
Phase 1 · 11 location(s) · IDEAYA Biosciences · NCT07540572CT-95 in Advanced Cancers Associated With Mesothelin Expression
Phase 1 · 9 location(s) · Context Therapeutics Inc. · NCT06756035Dual-Targeting CAR-NK Cells in Biomarker-Selected Advanced Colorectal Cancer
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07589517A Study to Test Different Doses of BI 765049 in People With Advanced Cancer of the Colon, Rectum, Stomach, or Pancreas
Phase 1 · 3 location(s) · Boehringer Ingelheim · NCT06882746Oral Chemotherapy, Targeted Therapy and Immunotherapy With/Without Radiotherapy as 3rd- or Later-line Therapy for Advanc
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT06764680Study of IBI3028 in Participants With Locally Advanced, Unresectable, or Metastatic Solid Tumors
Phase 1 · 1 location(s) · Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. · NCT07589205EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Essen Biotech · NCT07410676A Phase 1 Study to Evaluate TGI-6 in Subjects With Locally Advanced/Metastatic Solid Tumors
Phase 1 · 1 location(s) · Hefei TG ImmunoPharma Co., Ltd. · NCT06374173A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
Phase 1/Phase 2 · 14 location(s) · Astellas Pharma Global Development, Inc. · NCT07488676A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangement
Phase 1/Phase 2 · 165 location(s) · Turning Point Therapeutics, Inc. · NCT03093116A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumor
Phase 1/Phase 2 · 10 location(s) · A2 Biotherapeutics Inc. · NCT06682793Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
Phase 1/Phase 2 · 13 location(s) · Tasca Therapeutics · NCT07030257A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Phase 1/Phase 2 · 79 location(s) · Artios Pharma Ltd · NCT04657068A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
Phase 1 · 12 location(s) · Aktis Oncology, Inc. · NCT07020117CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With
Phase 2 · 1 location(s) · Northwestern University · NCT05733000A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tum
Phase 1 · 6 location(s) · GlaxoSmithKline · NCT07277270Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherap
Phase 1/Phase 2 · 4 location(s) · Auricula Biosciences Inc. · NCT07148128FOG-001 in Locally Advanced or Metastatic Solid Tumors
Phase 1/Phase 2 · 33 location(s) · Parabilis Medicines, Inc. · NCT05919264
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.